

*Canadian HIV/AIDS Pharmacists (CHAP/ACPV) Network
Meeting Minutes
Montreal, Quebec
April 23, 2008*

Recorded by: Linda Akagi – Secretary
Reviewed by: Natalie Dayneka – Chair

Members Present:

BC: Linda Akagi, Gloria Tsang
Alberta: Cara Hills, Christine Hughes, Tamar Koleba, Kathy Lee
Saskatchewan: Linda Sulz
Ontario: Natalie Dayneka, Trish Marr, Charles la Porte, Linda Robinson
Quebec: Marie Courchesne, Niamh Higgins, Line Labbe, Suzanne Marcotte, Rachel Therrien
Newfoundland: Debbie Kelly

Working Group

Regrets: Michelle Foisy, Jeff Kapler, Jinell Mah-Ming, Lizanne Beique, Norman Dewhurst, Pierre Giguere, Alice Tseng, Deborah Yoong, Nancy Sheehan

Clinical Forum

- a. Perinatal/MTCT guidelines – general discussion amongst the members of the guidelines used at different sites. It was agreed that summarizing these differences in a document would be a suitable CHAP project.

***Action: Gloria and Tamar – Maternal management
Natalie – Newborn management***

- b. Natalie presented a clinical case that featured a low rifabutin level and an undetectable Kaletra level in a 9 yr old girl who was prescribed Kaletra, Combivir and rifabutin 150 mg every other day. The recommendation was to repeat the Kaletra levels (directly observed dose) at pre and 2-4 hours post dose and repeat the rifabutin level at 3 and 7 hours post dose. If the rifabutin level was still low, an increase to 150 mg daily could be considered.
- c. Patient Travel to the US with Antiretrovirals – US legislation to reverse the restriction for HIV individuals from entering the US is being considered. However, in the meantime, it was agreed that patients should be encouraged to take their antiretrovirals with them in a labeled prescription bottle (other than the manufacturer's bottle, which contains specific information about HIV). Trish Marr reported that the Toronto clinic provides a medical letter for patients that states that they are being treated for a chronic condition. The letterhead is general in nature and does not contain any HIV identifiers.
- d. Crushing Antiretrovirals – discussion about various tools available that provided information on crushing antiretrovirals, such as the DHHS pediatric guidelines and BAXA's 'dissolve a dose' system. BC Children's hospital has an old document on crushing medications that could be updated.
Action: Gloria to provide Christine with a copy of the BCCH document for updating as a residency project
- e. Narcotic Recovery from Inpatients – question regarding proper disposal of illegal medications that are recovered from inpatients. Suggested that these medications could be given to hospital security and then anonymously turned over to the police.
- f. Stopping Antiretrovirals – discussion about stopping antiretrovirals with different half lives. BC recently developed a patient card and information sheet that alerts patients to avoid this practice (see attached).
- g. HIV Testing
a. Pregnancy – differences across Canada highlighted with 'opt-in' vs 'opt-out' testing
b. Point of care – pilot, anonymous testing in Ontario

- h. Sexual Assault – discussion of guidelines for post exposure prophylaxis
Action: Linda R to provide SAOTO document
- i. Medication Reconciliation – Trish led a discussion of a medication reconciliation tool provided through the Safer Healthcare Now link. The group agreed that this could be a possible CHAP/ACPV project and that there could be support available through the Institute for Safe Medication Practices (ISMP).
Action: Trish, Niamh, Marie to send out proposal as a CHAP/ACPV project

TDM – Clinical Practice and Research – State of the Art

Niamh provided statistics (May 2006 – April 2007) from the Quebec TDM program. Charles led a group discussion on the clinical utility of employing TDM. It was agreed that pediatrics was a population that would benefit from an increased use of TDM. 2 possible CHAP projects were identified: differences in antiretroviral levels after opening capsules or crushing tablets and TDM in pregnancy that is linked to clinical outcomes.

**Action: Charles – to consider TDM study looking at opened/crushed antiretrovirals (atazanavir, Atripla, Truvada)
Niamh, Christine – to consider TDM study in pregnancy**

Business Meeting:

1. CHAP/ACPV Executive for 2008/09
Chair – Linda Akagi
Responsibilities: organize 2009 annual general meeting; CAHR delegate

Secretary/Chair-Elect – Cara Hills
Responsibilities: 2 newsletters (agreed to not include summarization of CHAP emails), minutes of 2009 annual general meeting
2. International Members – Natalie has received a request from an international pharmacist to be included in the CHAP/ACPV email exchange. The group agreed that this would be appropriate.
Action: any requests for inclusion in the CHAP/ACPV listserv from international pharmacists are to be forwarded to the Chair
3. Travel Grant Allocation Policy – discussion regarding travel grant to subsidize travel to the annual general meeting. It was pointed out that the grant is not intended to fully cover all related travel expenses. It was also agreed that it is not appropriate to provide funding to members who are from the host city. Other considerations for provision of the travel grant include, regional and specialty representation and high-volume patient sites.

The grant amount will vary from year to year, depending upon the total of amount of monies that is available and the number of out of town members who wish to attend the meeting. It was also pointed out that the list of travel grant recipients is not necessarily the same as the list of working group members. However, if available funds were limited, working group executive members would receive priority.
**Action: Moved by Linda Sulz to adopt the Travel Grant Allocation policy as discussed
Seconded by Christine Hughes
Motion was unanimously carried**
4. Working Group Members – discussion and agreement regarding review of working group members. The list will be reviewed annually after the annual general meeting by the Past Chair. Working group members will be provided with the required qualifications and asked

to evaluated if these conditions are met. If a member does not respond back to the Past Chair, then they will be removed from the working group list. It was agreed that an exception for required conditions (eg. MAT leave) would be considered by the Past Chair.

Discussion regarding the numbers of working group members representing Montreal. It was agreed to add Niamh Higgins as a working group member.

**Action: Linda/Natalie to inform Alice to add Niamh to the list of working group members
Natalie will ask Alice if it is possible to create a mailing list that only includes working group members**

The working group CHAP/ACPV members for 2008/09 are:

BC:	Linda Akagi, Gloria Tsang
Alberta:	Michelle Foisy, Christine Hughes, Cara Hills, Jeff Kapler, Kathy Lee, Jinell Mah-Ming
Saskatchewan:	Linda Sulz
Ontario:	Lizanne Beique, Natalie Dayneka, Norman Dewhurst, Charles laPorte, Pierre Giguere, Linda Robinson, Alice Tseng, Deborah Yoong
Quebec:	Marie Courchesne, Line Labbe, Nancy Sheehan, Rachel Therrien, Niamh Higgins
Newfoundland:	Debbie Kelly

- 5 Terms of Reference – discussion of document that was drafted by Jeff Kapler. Several changes were made to the document during the meeting. The revised document will be circulated to all working group members after the meeting for review and voting.
Action: Natalie to send revised document to working group members for discussion/voting
- 6 CHAP/ACPV Endorsement Policy – examples of endorsement policies were circulated for discussion (CSHP and OPA tools). It was agreed that creation of a CHAP/ACPV endorsement policy would be helpful.
Action: Linda Robinson to recruit members to work on creating a CHAP/ACPV Endorsement policy
- 7 ID Congress, Toronto – Christine Hughes reported that this conference will be held in Toronto from June 18- 21, 2009 and that some of the CHAP members are involved in developing the program
- 8 AAHIVM – HIV Specialty for Pharmacists – Niamh Higgins reported that her initial contacts with AAHIVM indicated that this credentialing program was open to Canadian pharmacists. However, it is still unclear if the program is open to pharmacists with designations other than their PharmD.
- 9 Gilead Science Project – limited information received on Gilead’s Forum on HIV project. The group agreed that more information was required, before the group could discuss our participation.
Action: Natalie to get further information from Gilead on the project for the group
10. Brainstorming–CHAP/ACPV 2008/09 projects and their leads were reviewed.
 - Endorsement policy (Linda R. – see minutes above)
 - Pregnancy & TDM (Niamh, Christine)
 - Medication reconciliation (Trish, Marie, Niamh)
 - Maternal management (Gloria, Tamar)
 - Crushing tablet chart (Christine)
 - TDM on crushed/opened ARVs (Charles)
 - Regional summary for HIV exposed newborn management (Natalie)

Meeting adjourned: 2009 meeting to be held in Vancouver (details to be released, once available)